IBIO Projected Dividend Yield

Com Par $0.001 (New)/iBio Inc ( AMEX : IBIO )

iBio is a preclinical stage biotechnology company that utilizes its artificial intelligence (AI) for the development of precision antibodies. Co.'s technology stack of epitope-steering AI-engine allows it to target related regions of proteins with unprecedented precision enabling the creation of antibodies specific to relevant regions within large target proteins. Co.'s machine learning based antibody-optimizing StableHu™ technology, when coupled with its mammalian display technology, has been shown to support the Lead Optimization process and potentially reduces downstream risks. Co. also developed the EngageTx™ platform, which provides a CD3 T-cell engager antibody panel.

20 YEAR PERFORMANCE RESULTS